Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection

Jordan Lake, Takara Stanley, Caroline Apovian, Shalender Bhasin, Todd Brown, Jaqueline Capeau, Steven Grinspoon, Giovanni Guaraldi, Jaqueline Capeau, Steven K. Grinspoon, Giovanni Guaraldi, Esteban Martinez, Grace A. McComsey, Fred R. Sattler, and Kristine M. Erlandson

1Department of Medicine, University of Texas Health Science Center at Houston; 2Department of Pediatrics, Harvard University School of Medicine and Department of Pediatrics, Boston University School of Medicine, Massachusetts; 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; 4Department of Cell Biology and Metabolism, Univ-Paris 6, Inserm UMR9388, ICAN, Paris, France; 5Department of Medicine, University of California Los Angeles and 6Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles; 7Department of Medicine, McGill University, Montreal, Quebec, Canada; 8Department of Medicine, Harvard University School of Medicine, Boston, Massachusetts; 9Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy; 10Department of Medicine, University of Barcelona, Spain; 11Department of Medicine and Pediatrics, Case Western University, Cleveland, Ohio; and 12Department of Medicine, University of Colorado School of Medicine, Aurora

Background. Obesity and lipohypertrophy are common in treated human immunodeficiency virus (HIV) infection and contribute to morbidity and mortality among HIV-infected adults on antiretroviral therapy (ART).

Methods. We present a consensus opinion on the diagnosis, clinical consequences, and treatment of excess adiposity in adults with treated HIV infection.

Results. Obesity and lipohypertrophy commonly occur among HIV-infected adults on ART and may have overlapping pathophysiology and/or synergistic metabolic consequences. Traditional, HIV-specific, and ART-specific risk factors all contribute. The metabolic and inflammatory consequences of excess adiposity are critical drivers of non-AIDS events in this population. Although promising treatment strategies exist, further research is needed to better understand the pathophysiology and optimal treatment of obesity and lipohypertrophy in the modern ART era.

Conclusions. Both generalized obesity and lipohypertrophy are prevalent among HIV-infected persons on ART. Aggressive diagnosis and management are key to the prevention and treatment of end-organ disease in this population and critical to the present and future health of HIV-infected persons.

Keywords. human immunodeficiency virus (HIV); obesity; lipohypertrophy; antiretroviral therapy.

Non-AIDS events are leading causes of morbidity and mortality among human immunodeficiency virus (HIV)-infected adults in the modern treatment area. Critical drivers of non-AIDS events are the metabolic and inflammatory consequences of excess adiposity. The prevalence of obesity [1–4] before and after antiretroviral therapy (ART) initiation is increasing worldwide, and central lipohypertrophy persists [5–7]. Aggressive diagnosis and early intervention may prevent end-organ disease in this population. Here, we present a consensus opinion on the diagnosis, clinical consequences, and treatment of excess adiposity in adults with treated HIV infection.

DEFINITIONS

Overweight and obese states may result from a variety of factors [8], including an imbalance between calories consumed and expended that leads to fat accumulation, and may impair health. Body mass index (BMI) is a simple measure to classify body size in adults. Body mass index is defined as a person’s weight in kilograms divided by the square of their height in meters (kg/m²). The World Health Organization defines obesity as a BMI ≥30 kg/m² [9]. Although BMI typically correlates with total percentage of body fat, in persons with low muscle mass, a normal (18.5–24.9 kg/m²) BMI may represent excess adiposity. For this reason, some authorities define obesity as body fat >25% for men or >33% for women [10]; however, this requires specialized techniques for body fat measurement (such as dual-energy x-ray absorptiometry [DXA] or bioelectrical impedance analysis) that are less standardized and less readily obtainable in clinical practice.

In the setting of treated HIV, lipohypertrophy refers to localized abnormal fat accumulation, most commonly of the intra-abdominal compartment (visceral adipose tissue [VAT]), breasts, dorso-cervical area (buffalo hump), and/or as discrete

Received 22 November 2016; editorial decision 8 February 2017; accepted 22 February 2017; published online February 24, 2017.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/cix78
accumulations under the skin (lipomas). Lipohypertrophy can occur in >1 regions simultaneously, with or without concurrent peripheral fat loss in the limbs or face (lipoatrophy) [11]. The coexistence of lipohypertrophy and lipoatrophy is referred to as mixed lipodystrophy. The causes of lipohypertrophy are not fully understood. Confounding the matter, generalized obesity and central lipohypertrophy can overlap in an aging population with traditional and HIV-/ART-specific risk factors.

PATHOPHYSIOLOGY

Obesity
Obesity is often multifactorial [8]; sedentary lifestyle and intake of excess or poorer quality calories (saturated fats, processed sugars) are significant risk factors [12]. Age, genetics, comorbid diseases, alcohol, certain medications, and resting metabolic rate also contribute [13]. Additionally, aging is associated with physiologic central fat redistribution, adipocyte senescence, and chronic inflammation [14], which may be enhanced in HIV-infected individuals.

The gut microbiome may play an important role in obesity development [15]. Microbiome alterations in obesity include increased energy harvest from food [16]; altered secretion of gut hormones that affect satiety, such as glucagon-like peptide-1 (GLP-1) [17]; increased lipopolysaccharide shedding [18], leading to activation of inflammatory pathways that promote ectopic fat deposition; production of byproducts that alter insulin–glucose homeostasis [19]; and modulation of innate immunity and the autonomic nervous system [20]. Indeed, increased sympathetic (leading to leptin excess) and parasympathetic (stimulating adipogenesis) nervous system activity have been associated with obesity, particularly central adiposity [21]. Finally, activation of the renin-angiotensin system is associated with visceral adiposity and insulin resistance [22].

Fat type and distribution also influence clinical impact: In HIV-uninfected persons, VAT and subcutaneous adipose tissue (SAT) metabolism and inflammatory signatures vary, with VAT (and particularly hepatic fat) accumulation associated with more pronounced sequelae [23–25]. In HIV-infected persons on suppressive ART, VAT and SAT metabolic and inflammatory signatures are less well understood; however, less proinflammatory signal induction in VAT may protect this depot from fat loss and promote metabolic dysfunction and systemic inflammation [26].

Lipohypertrophy
The etiology of lipohypertrophy in treated HIV infection is multifactorial. There is likely a direct role for HIV: adipose tissue may serve as a reservoir for HIV, altering the local tissue environment and promoting enhanced adipose tissue inflammation [27]. Indeed, altered adipocyte differentiation and enhanced fat inflammation have been reported in ART-untreated HIV controllers [28]. HIV proteins (Tat, Nef, Vpr) alter adipose tissue function and increase inflammation in preclinical models [29]. Finally, the endoribonuclease DICER, which is downregulated by Vpr, is associated with lipohypertrophy and altered brown adipocyte function [30].

HIV-associated chronic inflammation and immune activation may play a direct role in the development of lipohypertrophy, with circulating CD8+ T-lymphocyte activation linked to VAT accumulation [31]. Similar to obesity, hormonal imbalances (eg, hypogonadism, growth hormone deficiency, renin-angiotensin system activation) and gut microbiome alterations may play adjunct roles [32–34].

Antiretroviral therapy’s role in lipohypertrophy and VAT accumulation is evolving. Although lipoatrophy in HIV-infected persons is mainly linked to the use of thymidine analog nucleoside reverse-transcriptase inhibitors (NRTIs) [35, 36], in the modern ART era patients are more likely to experience fat increases [37–39], and the role of ART in fat gain remains uncertain [40, 41]. In vitro, ritonavir-boosted protease inhibitors (PIs) induce cellular senescence, oxidative stress and inflammation, and accumulation of the senescence protein p21 in adipose tissue [42], as observed in buffalo hump fat with a brown fat-like phenotype [43, 44]. Additionally, multiple ART classes (including PIs, NRTIs, and non-NRTIs [NNRTIs]) have been associated with impaired adipogenesis, adipocyte differentiation, or function [45, 46]. Impairment of lipid and/or glucose metabolism by these agents further stimulates a proinflammatory environment detrimental to adipose tissue.

Clinical trials have assessed the role of ART in the development of lipohypertrophy. Overall, no differential effect of the NRTI or NNRTI classes has been observed. The integrase strand transfer inhibitor (INSTI) raltegravir led to similar VAT accumulation when compared with PIs [38], but the effects of other INSTIs remain uncertain. The role of PIs also remains uncertain. Although PIs do not generally lead to more lipohypertrophy than NNRTIs [47], ritonavir-boosted atazanavir may be an exception: when this specific PI was compared with NNRTIs and older PIs, there was a trend toward greater gains in central fat [48, 49]. However, ritonavir-boosted atazanavir and darunavir performed similarly in 2 other studies [38, 50].

CONSEQUENCES OF OBESITY AND LIPOHYPERTROPHY

Obesity likely has similar metabolic and inflammatory consequences in HIV-infected persons as in the general population (Figure 1). Obesity and lipohypertrophy, particularly VAT accumulation, are often associated with chronic inflammation in adipose tissue, insulin resistance [51–54], increased metabolic syndrome risk [55], dyslipidemia [56] and increased oxidative stress [57]; abdominal obesity is robustly associated with cardiovascular disease (CVD) risk and mortality [58–60]. However, for any given BMI, HIV infection appears to confer greater

Fat Gain in Treated HIV Infection • CID 2017:64 (15 May) • 1423
cardiovascular and metabolic consequences compared with matched HIV-uninfected populations [S61, S62].

Similarly, VAT changes of as little as 5% affect metabolic syndrome risk [S63], and obesity and increased VAT are known risk factors for diabetes mellitus (DM) and CVD [S63]. Obesity and lipo hypertrophy are usually pro-inflammatory states, and HIV-associated inflammation and immune activation could facilitate or perpetuate concomitant metabolic disease. Indeed, in some populations, HIV infection is associated with increased type 2 DM [S64] and CVD risk [S65, S66]. Central fat accumulation and ectopic fat deposition may contribute to CVD development through the release of proinflammatory mediators and their downstream effects. In HIV-infected patients, VAT, intrahepatic fat, and epicardial fat are associated with CVD independent of traditional CVD risk factors [S67–S69].

Poorer neurocognitive function was associated with increased waist circumference (WC) among HIV-infected participants in the CHARTER study [25]. Similarly, in the Multicenter AIDS Cohort Study, VAT was strongly associated with regional brain atrophy (which precedes neurocognitive decline), irrespective of HIV serostatus [S70].

Multimorbidity is the accumulation of multiple, serious chronic health conditions. In some cases, these conditions may interact to amplify morbidity and mortality [S71]. For example, obesity is directly associated with detrimental effects on muscle [S72]; obesity is also associated with osteoarthritis, neurocognitive dysfunction, CVD, and DM, which are associated with increased risk of physical function impairment or frailty [S73]. Overweight or obese HIV-infected individuals have a ≥67% prevalence of multimorbidity [S74].

Finally, in addition to metabolic and inflammatory consequences, body fat changes are stigmatizing and may impact self-esteem, affect ART adherence, lead to depression, and decrease quality of life [S75].

**CLINICAL ASSESSMENT OF OBESITY, LIPOHYPERTROPHY, AND THEIR SEQUELAE**

Body weight and BMI should be tracked at least yearly and weight gain addressed because prevention and early intervention are likely more effective than reversing fat accumulation. Because lower muscle mass [S76] can lower calculated BMI despite an increase in body fat [S77], we recommend annual measurement of WC for all HIV-infected persons [S78, S79]. Elevated WC is indicative of increased cardiometabolic risk regardless of BMI [S80]. Waist circumference cutoffs indicative of increased metabolic risk have been proposed by multiple groups, including the International Diabetes Foundation (≥94 cm for men, ≥80 cm for women) and US National Cholesterol Education Program (>102 cm for men, >88 cm for women) [S80, S81]. A minimum WC of 94 cm in women and 95 cm in men correlates with VAT

![Figure 1. Central role of the adipocyte in multisystem disease. Abbreviations: AT1/AT2, angiotensin II receptor type I/II; GLUT4, glucose transporter type 4; IRS1/2, insulin receptor substrate 1/2; MCP-1, monocyte chemotactic protein 1; NO, nitric oxide; PAI-1, plasminogen activator inhibitor 1; PPAR-γ, peroxisome proliferator-activated receptor-γ; TNF-α, tumor necrosis factor α. Adapted with permission from Macmillan Publishers Ltd, Kidney Int 2008;74(7):851–3.](image-url)
area ≥130 cm², a validated threshold for increased markers of cardiometabolic risk [S82, S83]. However, the WC cutoffs for metabolic risk and elevated VAT have not been validated in HIV-infected populations.

Although etiology and treatment strategies for generalized obesity and lipohypertrophy may differ, clinical distinction can be difficult because these conditions often coexist. A personal or family history of obesity and diffuse fat distribution supports the diagnosis of generalized obesity, whereas regional truncal or visceral fat accumulation supports the diagnosis of lipohypertrophy. Additionally, lipohypertrophy often becomes clinically visible at least 1–2 years after ART initiation. Although most standardized lipohypertrophy definitions include radiographic assessment of fat quantity [S84], use of imaging is primarily limited to research and not recommended in routine clinical practice [S85–S87]. Furthermore, lipohypertrophy definitions were established in cohorts with a high prevalence of mixed lipodystrophy and extensive exposure to older NRTIs [S88], making the validity of these definitions in the current ART era unknown.

Assessment for complications of obesity and lipohypertrophy should follow established obesity management guidelines [S78], with some notable exceptions: Fasting lipids and glucose should be measured annually and within 3 months of ART change [S89]. Dyslipidemia should be managed per available consensus guidelines [S90, S91], with the caveat that existing CVD risk scores may underestimate risk in HIV infection [S92]. Hemoglobin A1c may be useful, although increased red blood cell turnover in HIV infection may underestimate glycemia [S93]. Because nonalcoholic fatty liver disease occurs in 20%–40% of HIV-infected adults [S68, S94–S97] and is closely linked to obesity, visceral adiposity, and insulin resistance [S98], clinicians should have a low threshold to evaluate unexplained transaminase elevations [S94]. Secondary causes of new onset or worsening weight gain should be considered when relevant, including Cushing’s syndrome caused by corticosteroids coadministered with PIs or cobicistat [S99, S100]. In keeping with the screening recommendations above, we strongly recommend blood pressure and glycemic control, smoking cessation, and aspirin and/or statin use in all patients with appropriate risk profiles.

**MANAGEMENT OF OBESITY AND LIPOHYPERTROPHY**

**Lifestyle Changes**

Structured exercise with or without dietary intervention reduces abdominal obesity in most studies of HIV-infected persons [S101–S108]. Although no studies directly compare dietary and/or exercise interventions, studies with a dietary component have generally been effective in reducing weight and WC but have not consistently resulted in improved glucose metabolism [S101, S102, S109]. A higher fiber diet has been associated with reduced obesity [S110] but not VAT [S111]. Disproportionate SAT loss with diet or exercise has not been observed, providing reassurance that neither worsens preexisting lipodystrophy. One study found no benefit in adding exercise to a low-fat diet [S104]. Data on the efficacy of resistance versus aerobic training are lacking in this population.

In summary, data are insufficient to support any specific dietary or exercise strategy in patients with HIV and abdominal obesity. Although long-term lifestyle intervention adherence may be low, in persons with generalized or abdominal obesity we recommend ≥30 minutes of moderate-intensity physical activity most days of the week plus caloric restriction to ≥500 kcal/d below usual intake (guided by a nutrition professional) to attain and sustain 5%–10% weight loss [S112]. As in the general population, adjuvant behavioral therapy may be helpful in achieving sustained lifestyle modifications.

**Role of ART**

As above, initiation of NNRTI-, PI-, and INSTI-based ART is generally associated with SAT and VAT gain, although data are lacking with the newer INSTIs (elvitegravir and dolutegravir). Similarly, randomized switch studies have not shown a benefit of switching from a PI (Table 1).

**Medical Interventions**

**Obesity**

For patients without isolated central lipohypertrophy but BMI ≥27 kg/m² with comorbidity or BMI >30 kg/m² without comorbidity, pharmacologic treatment can be considered in addition to diet, exercise, and behavioral modification. There are 5 medications or medication combinations currently approved in the United States to treat obesity in the general population (Table 2), all of which can lead to clinically significant weight loss (25% over 1 year) [S113]. Because not all patients will respond, discontinuation or switch to another agent is recommended after 3 months if ≥5% weight loss has not been achieved [S114]. No agent has emerged as first-line therapy. Choice of medication depends on cost, availability, comorbidities, concomitant medications, and side effects. In the general population, phentermine/topiramate and liraglutide demonstrate the highest probability of achieving significant weight loss, whereas naltrexone/bupropion and liraglutide are associated with the highest rates of discontinuation due to an adverse event [S113]. Potential drug–drug interactions between antiobesity medication and ART are shown in Table 2.

In patients with DM, medications also associated with weight loss, including GLP-1 receptor agonists, should be considered. In patients with CVD or uncontrolled hypertension, sympathomimetics such as phentermine should be avoided [S114].

**Lipohypertrophy**

**Growth Hormone Axis Therapy.** Given growth hormone’s (GH’s) lipolytic effects and the association between reduced GH and increased VAT [S32, S115, S116], GH axis therapies have specifically been studied for VAT accumulation in HIV.
Recombinant human GH (rhGH) at supraphysiologic doses (1–6 mg daily) significantly decreases VAT, with some SAT reduction [S117–S121]. However, most studies demonstrate deleterious effects of rhGH on glucose homeostasis. Indeed, rhGH decreases glucose tolerance even at physiologic levels [S122]. Thus, rhGH was not approved by the US Food and Drug Administration for use in HIV-associated lipodystrophy [S123].

Tesamorelin, a GH-releasing hormone analog, is the only drug approved (in some countries) to reduce excess VAT in treated HIV infection. Tesamorelin increases endogenous pituitary GH release, reducing VAT by approximately 15% within 6 months among HIV-infected patients with baseline WC ≥95 cm for males or ≥94 cm for females [S124–S127]. Approximately two-thirds of patients respond to treatment without decreases in SAT [S127]. Increased fasting glucose may occur in a minority of patients and tends to be transient [S127–S129]. Tesamorelin is administered at a fixed dose of 2 mg subcutaneously daily. It has no known significant interactions with ART.

A limitation of tesamorelin is that VAT quantity returns to baseline, on average, by 6 months after discontinuation [S127]. Measuring WC as a VAT surrogate is recommended after 6 months of treatment, along with assessment of quality of life and lipid levels. Any reduction in WC may represent a meaningful reduction in VAT and should also be interpreted in the context of other factors, including patient well-being, quality of abdominal fat on exam, and change in glucose and lipid parameters. Treatment discontinuation should be considered in patients not achieving WC reduction by 6 months. Tesamorelin should be stopped if significant increases in fasting glucose or HbA1C develop. Although tesamorelin did not worsen glucose in diet-controlled diabetics [S124], it should be used cautiously in patients with diabetes, particularly those with suboptimal glycemic control. Tesamorelin is contraindicated in patients with active malignancy and those who are pregnant or trying to achieve pregnancy. Insulin-like growth factor 1 (IGF-1) levels should be monitored 6 months after initiation, with reduction or discontinuation if IGF-1 levels exceed the upper limit of normal. Injection site reactions require discontinuation in 2%–3% of patients [S124].

**Metformin.** Metformin improves insulin resistance in HIV-infected individuals with underlying metabolic disease.

### Table 1. Objective Changes in Central Fat Following Antiretroviral Therapy Initiation and Switch

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Subjects (no.)</th>
<th>Duration (wks)</th>
<th>Impact on Fat</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Randomized Trials of Initial Therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McComsey et al ACTG 5224a</td>
<td>ATV/r or EFV + ABC/3TC or TDF/FTC</td>
<td>269</td>
<td>96</td>
<td>Greater increase CT VAT area ATV/r (26%) vs EFV (12%); not statistically significant</td>
</tr>
<tr>
<td>Martinez et al ATADAR (50)</td>
<td>ATV/r or DRV/r + TDF/FTC</td>
<td>178</td>
<td>96</td>
<td>Greater increase DXA trunk fat ATV/r vs DRV/r; no significant VAT difference</td>
</tr>
<tr>
<td>McComsey et al ACTG 5260a</td>
<td>RAL, DRV/r or ATV/r + TDF/FTC</td>
<td>330</td>
<td>96</td>
<td>Similar increase CT VAT area (RAL, 29% DRV/r, 21%; ATV/r, 16%)</td>
</tr>
<tr>
<td>Moyle et al [49], CASTLE</td>
<td>ATV/r or LPV/r + TDF/FTC</td>
<td>224</td>
<td>96</td>
<td>Greater increase DXA trunk fat ATV/r vs LPV/r; no significant VAT difference</td>
</tr>
<tr>
<td>Vrouwenraets et al [48]</td>
<td>ATV/r or SQV/r + TDF/FTC</td>
<td>86</td>
<td>48</td>
<td>Greater increase DXA trunk fat and VAT ATV/r vs SQV/r; not statistically significant</td>
</tr>
<tr>
<td><strong>Switch Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moyle et al [S167]</td>
<td>PI -&gt;EFV</td>
<td>25</td>
<td>52</td>
<td>CT VAT area decreased 10%</td>
</tr>
<tr>
<td>Bickel et al PROTRA1 Study</td>
<td>PI -&gt;EFV</td>
<td>23</td>
<td>48</td>
<td>No change CT VAT area</td>
</tr>
<tr>
<td>Tebas et al [S169]</td>
<td>PI -&gt;NVP</td>
<td>40</td>
<td>24</td>
<td>No significant body composition changes DXA or MRI subset</td>
</tr>
<tr>
<td>Moyle et al [S170]</td>
<td>PI -&gt;ABC</td>
<td>27</td>
<td>48</td>
<td>No change CT VAT area</td>
</tr>
<tr>
<td>McComsey et al [S171] TARHEEL Study</td>
<td>d4T -&gt; ABC or AZT</td>
<td>118</td>
<td>48</td>
<td>CT VAT area decreased 4%; CT SAT area decreased 32%</td>
</tr>
<tr>
<td>Moyle et al [S172]</td>
<td>d4T or AZT-&gt; TDF or ABC</td>
<td>105</td>
<td>104</td>
<td>TDF and ABC modest increases DXA SAT; no significant VAT changes</td>
</tr>
<tr>
<td>Tebas et al [S173] ACTG AS110</td>
<td>d4T or AZT-&gt; ABC, LPV/r + NVP or delayed switch</td>
<td>101</td>
<td>48</td>
<td>Both arms: increased CT SAT area and decreased VAT-total fat ratio Switch to ABC reduced CT VAT area</td>
</tr>
<tr>
<td>Curran et al [S174] SPIRAL-LIP Study</td>
<td>Pl/r -&gt;RAL or continued Pl/r</td>
<td>74</td>
<td>48</td>
<td>RAL: no significant CT VAT or SAT change Pl/r: increased CT total abdominal fat and VAT area</td>
</tr>
<tr>
<td>Lake et al [S175] Wi-Fat Study</td>
<td>Pl or NNRTI -&gt; RAL or delayed switch</td>
<td>37</td>
<td>48</td>
<td>No significant CT SAT or VAT area changes</td>
</tr>
<tr>
<td>John et al [S176]</td>
<td>d4T or AZT + 3TC + PI -&gt; AZT + 3TC + ABC or continue current</td>
<td>37</td>
<td>48</td>
<td>Increased DXA SAT; no change in CT VAT area</td>
</tr>
<tr>
<td>Stanley et al [S177]</td>
<td>LPV/r -&gt;ATV/r</td>
<td>14</td>
<td>24</td>
<td>Significant decrease in CT VAT area</td>
</tr>
</tbody>
</table>

**Abbreviations:** 3TC, lamivudine; ABC, abacavir; ACTG, AIDS Clinical Trials Group; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; CT, computed tomography; d4T, stavudine; DRV/r, ritonavir-boosted darunavir; DXA, dual x-ray absorptiometry; EFV, efavirenz; FTC, emtricitabine; LPV/r, ritonavir-boosted lopinavir; MRI, magnetic resonance imaging; NVP, nevirapine; PI/r, ritonavir-boosted protease inhibitor; RAL, raltegravir; SAT, subcutaneous adipose tissue; SQV, saquinavir; TDF, tenofovir disoproxil fumarate; VAT, visceral adipose tissue.
Table 2. Potential Drug Reactions and Interactions Between Antiretroviral Therapy and Antiobesity Medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>Maximum Dose¹</th>
<th>Mechanism of Action</th>
<th>Side Effects</th>
<th>ART Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orlistat</td>
<td>120 mg TID</td>
<td>Pancreatic/gastric lipase inhibitor</td>
<td>↓ fat-soluble vitamin absorption, steatorrhea, fecal incontinence</td>
<td>Avoid: Loss of virologic control reported in patients taking ATV/r or EFV [S178, S179].</td>
</tr>
<tr>
<td>Phentermine/Topiramate</td>
<td>7.5 mg/46 mg QD</td>
<td>Norepinephrine releasing agent/GABA receptor modulation</td>
<td>Insomnia, dry mouth, constipation, paraesthesia, dizziness, dysgeusia</td>
<td>Caution: Topiramate is a mild CYP3A4 inducer, but clinical relevance is unlikely [S180].</td>
</tr>
<tr>
<td>Lorcaserin</td>
<td>10 mg BID</td>
<td>5HT2c receptor agonist</td>
<td>Headache, nausea, dry mouth, dizziness, fatigue, constipation</td>
<td>None</td>
</tr>
<tr>
<td>Naltrexone/ Bupropion</td>
<td>8 mg/90 mg, 2 tabs BID</td>
<td>Dopamine/norepi-nephrine reuptake inhibitor/opioid antagonist</td>
<td>Nausea, constipation, headache, vomiting, dizziness</td>
<td>Caution: Bupropion CYP2B6 metabolized [S181]. EFV or RTV use may decrease concentrations. Clinical monitoring and standard bupropion doses recommended.</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>3 mg daily</td>
<td>GLP-1 agonist</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ART, antiretroviral therapy; ATV/r, ritonavir-boosted atazanavir; BID, twice daily; CYP2B6, cytochrome P450 2B6; CYP3A4, cytochrome P450 3A4; EFV, efavirenz; GABA, gamma-aminobutyric acid; GLP-1, glucagon-like peptide-1; MAOI, monoamine oxidase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; QD, once daily; RTV, ritonavir; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TID, three times daily.

²Please see prescribing information for specific details including starting dose and dose titration.

[S130–S136], and some studies show lipid [S131, S136–S138] and blood pressure benefits [S134]. Metformin is associated with small decreases in BMI (typically ≤1 kg/m²) [S131, S134, S135, S137], with proportional reductions in VAT in some, but not all, studies [S133, S134, S136–S139]. Metformin also improves markers of fibrinolysis [S135, S140] and endothelial function [S138] and decreases progression of coronary artery calcium [S130]. Thus, in patients with lipohypertrophy, particularly those with impaired glycemia, we recommend (off-label) consideration of metformin for its potential metabolic and cardiovascular benefits rather than specific (and potentially modest) effects on BMI or VAT. Of note, concomitant duloxetine administration increases metformin concentrations such that 1000 mg daily of metformin is the maximum recommended dose [S141, S142].

Other Agents. The thiazolidinediones (TZDs) rosiglitazone and pioglitazone improve insulin sensitivity [S133, S138, S143–S146] with no effect or an increase in SAT or VAT [S133, S138, S143–S145, S147]. Thus, we do not recommend TZDs for the treatment of lipohypertrophy. Recombinant human leptin (metreleptin) provides metabolic benefit and VAT reduction in HIV-infected persons with severe lipodystrophy and decreased leptin levels in small studies [S148–S150] but is neither indicated nor approved by the US Food and Drug Administration for the treatment of HIV-associated lipohypertrophy. Physiologic testosterone replacement may be considered for patients with hypogonadism assessed by measuring morning free testosterone with a reliable assay [S151] and may decrease overall fat mass [S152]. However, testosterone has not been shown to decrease VAT in HIV [S152], and lipohypertrophy per se is not an indication for testosterone supplementation in HIV-infected adults.

Surgical Interventions

Obesity

Weight-loss (bariatric) surgery is the most effective treatment for obesity, resulting in an average 60%–70% loss of excess body weight and marked improvements in obesity-related conditions [S153–S155]. There are limited data regarding safety and efficacy in HIV, but in small case series, both Roux-en-Y gastric bypass and vertical sleeve gastrectomy appear to be safe, without changes in virologic control or ART drug concentrations [S156–S160]. However, transient but reversible reductions in tenofovir disoproxil fumarate concentrations were recently reported following vertical sleeve gastrectomy without CD4⁰ T lymphocyte count or HIV-1 RNA alterations [S161], and a more definitive study of ART pharmacokinetics after bariatric surgery is needed. Bariatric surgery should be considered in persons with a BMI ≥40 kg/m² or a BMI ≥35 kg/m² with obesity-related comorbidities that are refractory to serious attempts at lifestyle changes.

Lipohypertrophy

HIV-infected individuals with dorsocervical or anterior cervical fat accumulation and pain and/or functional limitations may be candidates for surgical intervention, including suction-assisted lipectomy and dermolipectomy. Fat accumulation may recur, however, requiring repeat procedures. Large studies are lacking, with case studies reporting recurrence rates from 0%–50% [S162–S166]. Data on the metabolic effects of surgical fat removal are also lacking. To our knowledge, there are no reports of surgical omentectomy in HIV-infected patients.
CONCLUSIONS

Obesity and lipohypertrophy are common disease states in treated HIV infection that may have overlapping pathophysiological and/or synergistic metabolic consequences. Prevention and treatment of these disease states are critical to the present and future health of HIV-infected persons. Although promising treatment strategies exist, further research is needed to better understand the pathophysiology and optimal treatment of obesity and lipohypertrophy in the modern ART era.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank Michelle Foisy for her assistance in interpreting potential pharmacologic interactions.

Financial support. This work was supported by National Institutes of Health grants K23 AI110532 to J. E. L., K23 AG050260 to K. M. E., and K24 AI120834 to T. T. B.

Potential conflicts of interest. J. E. L. has received research funding through her institution from Gilead Sciences and served as a consultant to Gilead Sciences and GSK. T. S. has received investigator-initiated funding from Kowa and Novo Nordisk and has served on an advisory board to Theratechnologies. C. A. has served as a consultant for Merck, Nutrisystem, Zaügen, Sanofi-Aventis, Orexigen, Enteromedics, Scientific Intake, Gelesis, Ferring, Takeda, and Novo Nordisk; has received research funding from Aspire Bariatrics, GI Dynamics, Pfizer, Gelesis, Orexigen, MetaProteomics, Takeda, The Dr Robert C. and Veronica Atkins Foundation, and MYOS Corporation; and owns stock in Science Smart LLC. S. B. has received grant support from AbbVie Pharmaceuticals, Transition Therapeutics, Takeda Pharmaceuticals, and Eli Lilly, Inc. for investigator-initiated research unrelated to this study; served as a consultant to AbbVie, Regeneron, Novartis, and Eli Lilly & Co.; and has a financial interest in Function Promoting Therapies, LLC. T. T. B. has served as a consultant to Gilead Sciences, Merck, BMS, EMD-Serono, and Theratechnologies. J. C. has received research grants paid to her university from ViiV, MSD, and Janssen, and has served on speaker's bureaus for ViiV, MSD, Janssen, Gilead Science, Chugai, and Novartis. J. S. C. has received research support through her institution from Theratechnologies. M. P. D. has served as a consultant for Gilead and Astra Zeneca, and receives research funding from Gilead, ViiV, BMS, and Merck. J. F. has served as a consultant to Theratechnologies, and served on speaker's bureaus or advisory boards for ViiV, Merck, Serono-MSD, and Theratechnologies. S. K. G. has received research support through his institution from Navidea, Theratechnologies, Kowa, and Gilead, and served as a consultant to Navidea and Theratechnologies. G. G. has received research support and served as a consultant to Gilead Sciences, Merck, and ViiV, and served as a speaker for Gilead Sciences, Merck, ViiV, Janssen, and BMS. E. M. has received honoraria, speakers' fees, consultant fees, and/or research funds from Gilead, Janssen-Cilag, MSD, and ViiV. G. A. M. has received grant support from Gilead, BMS, and Merck, and served as a consultant to Gilead, ViiV, ICON, and BMS. F. R. S. has served as a consultant to Theratechnologies. K. E. M. has received research funding to her institution from Gilead Sciences, and served as a consultant to Theratechnologies. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

REFERENCES

10. Hambly ODG, Oral EA obesity practice essentials. Medscape 2016. Available at: http://emedicine.medscape.com/article/123702-overview?tp=FtUtYPPdEss-lseqanTz9mQz7jvbM9iuDrUOqEOcFmSj9b%2BSCyQ2jylJK12%2FsCTF-3wx2Tui1U792esvYl1%3D.